TY - JOUR
T1 - Serological bone markers and joint damage in early polyarthritis
AU - Jansen, Louise M.A.
AU - Van Der Horst-Bruinsma, Irene E.
AU - Lems, Willem F.
AU - Van Schaardenburg, Dirkjan
AU - Van De Stadt, Rob J.
AU - De Koning, Margret H.M.T.
AU - Dijkmans, Ben A.C.
PY - 2004/8
Y1 - 2004/8
N2 - Objective. To investigate the relationship between osteocalcin (OC), a marker of bone formation, and the recently developed serum marker of bone resorption, β-C-telopeptide (β-CTx), and radiographic damage in patients with early oligo- and polyarthritis. Methods. Patients with peripheral arthritis of ≥ 2 joints and < 2 years of symptom duration were studied. The OC and β-CTx concentrations at baseline were correlated with disease activity and radiographic damage at baseline, and with radiographic progressive disease after 2 years (delta Sharp/van der Heijde score ≥ 5). The additional value of serum bone metabolism markers to predict radiographic progressive disease was compared to that of established prognostic factors by multivariate logistic regression analysis. Results. Two hundred seventy-nine patients (67% female; median age 56 yrs, range 18-83) were included in the study, of whom 73% were diagnosed with rheumatoid arthritis (RA). Baseline levels of β-CTx (p < 0.05) were significantly correlated with baseline radiographic damage whereas OC was not. β-CTx was also significantly (p < 0.001) related to measures of disease activity like erythrocyte sedimentation rate, C-reactive protein, and the disease activity score DAS28. Radiographic progressive disease after 2 years corresponded univariately with increased levels of β-CTx (p < 0.001), but not with OC. In multivariate analysis, β-CTx was not superior to other measures of radiographic progressive disease such as autoantibodies and disease activity. Conclusion. Increased serum levels of the bone turnover marker β-CTx are associated with radiographic damage at baseline and radiographic progression after 2 years. However, β-CTX is less predictive than markers already in use.
AB - Objective. To investigate the relationship between osteocalcin (OC), a marker of bone formation, and the recently developed serum marker of bone resorption, β-C-telopeptide (β-CTx), and radiographic damage in patients with early oligo- and polyarthritis. Methods. Patients with peripheral arthritis of ≥ 2 joints and < 2 years of symptom duration were studied. The OC and β-CTx concentrations at baseline were correlated with disease activity and radiographic damage at baseline, and with radiographic progressive disease after 2 years (delta Sharp/van der Heijde score ≥ 5). The additional value of serum bone metabolism markers to predict radiographic progressive disease was compared to that of established prognostic factors by multivariate logistic regression analysis. Results. Two hundred seventy-nine patients (67% female; median age 56 yrs, range 18-83) were included in the study, of whom 73% were diagnosed with rheumatoid arthritis (RA). Baseline levels of β-CTx (p < 0.05) were significantly correlated with baseline radiographic damage whereas OC was not. β-CTx was also significantly (p < 0.001) related to measures of disease activity like erythrocyte sedimentation rate, C-reactive protein, and the disease activity score DAS28. Radiographic progressive disease after 2 years corresponded univariately with increased levels of β-CTx (p < 0.001), but not with OC. In multivariate analysis, β-CTx was not superior to other measures of radiographic progressive disease such as autoantibodies and disease activity. Conclusion. Increased serum levels of the bone turnover marker β-CTx are associated with radiographic damage at baseline and radiographic progression after 2 years. However, β-CTX is less predictive than markers already in use.
KW - Bone turnover markers
KW - Early polyarthritis
KW - Joint damage
UR - http://www.scopus.com/inward/record.url?scp=3442887685&partnerID=8YFLogxK
M3 - Article
C2 - 15290726
AN - SCOPUS:3442887685
VL - 31
SP - 1491
EP - 1496
JO - Journal of rheumatology
JF - Journal of rheumatology
SN - 0315-162X
IS - 8
ER -